Healthcare Economist October 26, 2023
Jason Shafrin

If you guessed manufacturers, you would be incorrect. At least that is according to a new study by Mattingly et al. (2023) in JAMA Health Forum. Using a sample of the 45 generic drugs with >$100m in Part D and used by >1m beneficiaries, the authors found that:

…Medicare Part D spent $11.8 billion for 690 million claims (mean, $22.50 per claim; 95% CI,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Medicare, Pharma, Pharma / Biotech
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
Key Trends in the Evolution of PBMs and Their Future Impact on Drug Pricing and Pharmacy Operations

Share This Article